Allakos Inc. (ALLK)
Allakos Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Carlos, CA, US. The stock last traded at $0.33, up 0.22% on the session, giving a market capitalisation of $29.7M. On trailing twelve-month figures it carries a trailing P/E of -0.25, a net margin of 0.0%. Its beta of 0.14 implies it has historically moved less than the broad market.
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.
Allakos Inc. is most often compared with the following Healthcare names: